Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Restart Life SciencesFRA:HN30 32 Days Payable is 0.00 as of Jun. 2026. GuruFocus rates FRA:HN30 with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 709 Biotechnology companies, Restart Life Sciences ranks better than 85.9% on this metric.
Restart Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Restart Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HN30 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Restart Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Restart Life Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Restart Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Restart Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Restart Life Sciences (FRA:HN30) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Restart Life Sciences and its competitors. Over the past decade, Restart Life Sciences' Days Payable has ranged from 267.40 to 21,170.00. According to the industry distribution chart, Restart Life Sciences ranks #100 out of 709 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Restart Life Sciences' Days Payable too high?
Restart Life Sciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 267.40 to a high of 21,170.00. Based on the distribution chart, Restart Life Sciences ranks #100 out of 709 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Restart Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Restart Life Sciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #100 out of 709 companies for Days Payable. This places Restart Life Sciences in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.24. Historically, Restart Life Sciences' own Days Payable has ranged from 267.40 to 21,170.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 709 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Restart Life Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Restart Life Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (FRA:HN30) has a current Days Payable of 0.00. The current Days Payable is 0.00. Restart Life Sciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Restart Life Sciences (FRA:HN30), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.
32GF Score
Get the complete analysis for FRA:HN30
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HN30 has been successfully added to your 
